Tan, C. R., Derkach, A., Nemirovsky, D., Ciardiello, A., Diamond, B., Hultcrantz, M., . . . Korde, N. (2023). Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood cancer journal (New York), 13(1), 112-8. https://doi.org/10.1038/s41408-023-00882-y
Citace podle Chicago (17th ed.)Tan, Carlyn Rose, et al. "Bortezomib, Lenalidomide and Dexamethasone (VRd) Vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma." Blood Cancer Journal (New York) 13, no. 1 (2023): 112-8. https://doi.org/10.1038/s41408-023-00882-y.
Citace podle MLA (9th ed.)Tan, Carlyn Rose, et al. "Bortezomib, Lenalidomide and Dexamethasone (VRd) Vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma." Blood Cancer Journal (New York), vol. 13, no. 1, 2023, pp. 112-8, https://doi.org/10.1038/s41408-023-00882-y.